S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Rosa Ayala, Nieves Lopez, Adi Shacham Abulafia, Maan Alwan, Costas K. Yannakou, Indu Raman, Vincent Ribrag, Chun Yew Fong, Yulia Volchek, Massimiliano Bonifacio, Alessandra Tucci, Jean-Jacques Kiladjian, Jésus Marïa Hernandez Rivas, Blanca Xicoy, Haifa Kathrin Al-Ali, Jean-Christope Ianotto, Si Tuen Lee-Hoeflich, Sharmilla Das, Bin Wu, Palanikumar Ravindran, Qian Zhao, Guan Wang, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, David Lavie
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Wiley 2023-08-01
Seri Bilgileri:	HemaSphere
Online Erişim:	http://journals.lww.com/10.1097/01.HS9.0000967764.47851.65
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller